BACKGROUND: Improved and more frequent radiologic evaluation has resulted in increased identification of renal masses of unknown origin, which frequently pose a diagnostic dilemma for urologists. OBJECTIVE: Carbonic anhydrase IX (CAIX) is an antigen ubiquitously expressed in clear cell renal cell carcinoma (ccRCC). The specific and high level of expression in ccRCC makes CAIX an excellent target for imaging ccRCC lesions. We present our experience with immuno-single-photon emission computed tomography (immunoSPECT) imaging with the indium-111 ((111)In)-labeled anti-CAIX antibody girentuximab in patients presenting with either a primary renal tumor or a history of ccRCC and lesions suspect for metastases during follow-up. DESIGN, SETTING, AND PARTICIPANTS: Twenty-nine patients received 100-200 MBq (111)In-labeled girentuximab. Whole-body and single photon emission computed tomography (SPECT) images were acquired after 4-7 d. INTERVENTION: Injection with (111)In-girentuximab and image acquisition after 4-7 d. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Accuracy of (111)In-girentuximab immunoSPECT. RESULTS AND LIMITATIONS: Distinct uptake of (111)In-girentuximab was seen in 16 of 22 patients presenting with a renal mass. All renal masses proven to be ccRCC after resection (n=15) were detected with (111)In-girentuximab. Suspect lesions of six patients showed no uptake of (111)In-girentuximab. In these patients, ccRCC was not found, nor progression occurred. Seven patients with a history of ccRCC and possible metastatic lesions on follow-up computed tomography scans were imaged with (111)In-girentuximab. In four of these patients, the lesions showed preferential uptake of (111)In-girentuximab and local or systemic treatment was initiated. In three other cases, no (111)In-girentuximab targeting was seen. During follow-up of these three patients, one showed progression, for which systemic treatment was started. In the two other patients, no progression occurred, suggesting a benign nature. CONCLUSIONS: (111)In-girentuximab immunoSPECT can be used to detect ccRCC lesions in patients with a primary renal mass and to clarify the nature of lesions suspect for metastases in patients with a history of ccRCC.
BACKGROUND: Improved and more frequent radiologic evaluation has resulted in increased identification of renal masses of unknown origin, which frequently pose a diagnostic dilemma for urologists. OBJECTIVE:Carbonic anhydrase IX (CAIX) is an antigen ubiquitously expressed in clear cell renal cell carcinoma (ccRCC). The specific and high level of expression in ccRCC makes CAIX an excellent target for imaging ccRCC lesions. We present our experience with immuno-single-photon emission computed tomography (immunoSPECT) imaging with the indium-111 ((111)In)-labeled anti-CAIX antibody girentuximab in patients presenting with either a primary renal tumor or a history of ccRCC and lesions suspect for metastases during follow-up. DESIGN, SETTING, AND PARTICIPANTS: Twenty-nine patients received 100-200 MBq (111)In-labeled girentuximab. Whole-body and single photon emission computed tomography (SPECT) images were acquired after 4-7 d. INTERVENTION: Injection with (111)In-girentuximab and image acquisition after 4-7 d. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Accuracy of (111)In-girentuximab immunoSPECT. RESULTS AND LIMITATIONS: Distinct uptake of (111)In-girentuximab was seen in 16 of 22 patients presenting with a renal mass. All renal masses proven to be ccRCC after resection (n=15) were detected with (111)In-girentuximab. Suspect lesions of six patients showed no uptake of (111)In-girentuximab. In these patients, ccRCC was not found, nor progression occurred. Seven patients with a history of ccRCC and possible metastatic lesions on follow-up computed tomography scans were imaged with (111)In-girentuximab. In four of these patients, the lesions showed preferential uptake of (111)In-girentuximab and local or systemic treatment was initiated. In three other cases, no (111)In-girentuximab targeting was seen. During follow-up of these three patients, one showed progression, for which systemic treatment was started. In the two other patients, no progression occurred, suggesting a benign nature. CONCLUSIONS: (111)In-girentuximab immunoSPECT can be used to detect ccRCC lesions in patients with a primary renal mass and to clarify the nature of lesions suspect for metastases in patients with a history of ccRCC.
Authors: Baris Turkbey; Maria L Lindenberg; Stephen Adler; Karen A Kurdziel; Yolanda L McKinney; Juanita Weaver; Cathy D Vocke; Miriam Anver; Gennady Bratslavsky; Philip Eclarinal; Gideon Kwarteng; Frank I Lin; Nana Yaqub-Ogun; Maria J Merino; W Marston Linehan; Peter L Choyke; Adam R Metwalli Journal: Abdom Radiol (NY) Date: 2016-01
Authors: Karim Chamie; Nicholas M Donin; Pia Klöpfer; Paul Bevan; Barbara Fall; Olaf Wilhelm; Stephan Störkel; Jonathan Said; Michael Gambla; Robert E Hawkins; Gustavo Jankilevich; Anil Kapoor; Evgeny Kopyltsov; Michael Staehler; Kimmo Taari; Alberto J A Wainstein; Allan J Pantuck; Arie S Belldegrun Journal: JAMA Oncol Date: 2017-07-01 Impact factor: 31.777
Authors: Ravindra A De Silva; Michael A Gorin; Ronnie C Mease; Il Minn; Ala Lisok; Donika Plyku; Sridhar Nimmagadda; Mohamad E Allaf; Xing Yang; George Sgouros; Steven P Rowe; Martin G Pomper Journal: J Labelled Comp Radiopharm Date: 2021-03-04 Impact factor: 1.921
Authors: Jeannette C Oosterwijk-Wakka; Otto C Boerman; Peter F A Mulders; Egbert Oosterwijk Journal: Int J Mol Sci Date: 2013-05-29 Impact factor: 5.923